Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore the question of which is better for daily expenses: cash back or points. Make informed choices to maximize your rewards potential.
27,346 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A near-retiree couple with a $1.4 million 401(K) eye a $25,000-a-year consulting offer, only to learn Medicare IRMAA ...
Meta Platforms is signaling a bold pivot toward AI-focused cloud capacity. This article breaks down what neocloud wou...
In February 2026, a disciplined $1,000 starter plan can still unlock meaningful exposure to AI-driven growth. This re...
Disney, McDonald’s, Microsoft, and Procter & Gamble now appear oversold despite solid earnings and durable consumer s...
In a hypothetical mid-June scenario, SpaceX launches a historic $1.75 trillion IPO, raising $85.7 billion and closing...
Set a weekly ritual to translate headlines into a smarter portfolio. This Thursday reads guide shows you how to pick ...
As the EU tightens its MiCA rules, BitGo CEO warns of a potential massive stablecoin crisis if USD-backed issuers fai...
J.B. Hunt edges ahead on margin strength in a soft freight market, while ZIM faces a sharp drop in rates and merger r...
Archer Aviation sits at a pivotal crossroads as FAA progress updates loom and defense contracts lurk in the wings. Th...
Six non-AI chip makers could be poised to benefit from the AI boom, as demand broadens beyond headline AI chips. Here...
Bank of America issues two contrasting Buy ratings, backing Tesla’s autonomy roadmap and GM’s truck-led profitability...